Quantum BioPharma's 'unbuzzd' Clinical Trial Published, Demonstrating Accelerated Alcohol Metabolism and Reduced Intoxication
QNTM is trading near its 52-week low of $2.07 (11% above the low).
Summary
Quantum BioPharma announced the peer-reviewed publication of a clinical trial for its 'unbuzzd' dietary supplement, demonstrating significant acceleration of alcohol metabolism and reduction of intoxication symptoms.
Key Events · Product Development and Regulatory · QNTM
-
Peer-Reviewed Clinical Trial Publication
The double-blind, randomized, placebo-controlled clinical trial for 'unbuzzd' was published in the World Journal of Pharmaceutical and Medical Research.
-
Accelerated Alcohol Metabolism
The trial demonstrated that 'unbuzzd' dramatically and rapidly reduced blood alcohol concentration (BAC) in participants, with a rate over 40% faster within the first 30 minutes compared to placebo.
-
Reduced Intoxication and Hangover Symptoms
'unbuzzd' significantly improved alertness, stabilized heart rate and blood pressure, reduced perceived impairment and mental fatigue, and provided a 67% reduction in headache severity for hangover relief.
-
Significant Financial Interest
Quantum BioPharma retains 19.86% ownership in Unbuzzd Wellness Inc. and is entitled to 7% royalties on 'unbuzzd' sales until payments total $250 million, then 3% in perpetuity.
Analysis · QNTM · Life Sciences
This peer-reviewed publication provides strong scientific validation for 'unbuzzd', a product from which Quantum BioPharma derives significant royalty payments and retains pharmaceutical development rights. For a micro-cap company, this clinical validation could substantially boost sales of 'unbuzzd', directly impacting Quantum BioPharma's revenue stream and potentially opening doors for future pharmaceutical applications, representing a major positive catalyst.
At the time of this filing, QNTM was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $2.07 to $38.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.